ReviewGut microbes
Intestinal microbiota and blue baby syndrome: probiotic therapy for term neonates with cyanotic congenital heart disease.
Review in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01810978 (Efficacy of Synbiotics in Infants With Cyanotic Congenital Heart Disease), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Synbiotics in Infants With Cyanotic Congenital Heart Disease
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Probiotic administration in congenital heart disease: a pilot study.Journal of perinatology : official journal of the California Perinatal Association · 2013Trial
- Prevalence and outcomes of postoperative infection among pediatric congenital heart disease patients in intensive care units: a single center retrospective study.BMC infectious diseases · 2026Article
- Potential Impact of a Pregnant Woman's Microbiota on the Development of Fetal Heart Defects: A Review of the Literature.Biomedicines · 2024Review
- Oxygenation and intestinal perfusion and its association with perturbations of the early life gut microbiota composition of children with congenital heart disease.Frontiers in microbiology · 2024Article
- Particular genomic and virulence traits associated with preterm infant-derived toxigenic Clostridium perfringens strains.Nature microbiology · 2023Article
- Intestinal microbiome changes in an infant with right atrial isomerism and recurrent necrotizing enterocolitis: A case report and review of literature.World journal of clinical cases · 2022Article
- Analyzing the Complicated Connection Between Intestinal Microbiota and Cardiovascular Diseases.Cureus · 2022Review
- Disorders of gut microbiota in children with Tetralogy of Fallot.Translational pediatrics · 2022Article
- Necrotizing Enterocolitis in Children with Congenital Heart Disease: A Literature Review.Pediatric cardiology · 2021Review
- Dysbiosis and Intestinal Barrier Dysfunction in Pediatric Congenital Heart Disease Is Exacerbated Following Cardiopulmonary Bypass.JACC. Basic to translational science · 2021Article
- Human Milk Use in the Preoperative Period Is Associated with a Lower Risk for Necrotizing Enterocolitis in Neonates with Complex Congenital Heart Disease.The Journal of pediatrics · 2019Article
- Hypoxia induces senescence of bone marrow mesenchymal stem cells via altered gut microbiota.Nature communications · 2018Article
- A pilot study of Bifidobacterium breve in neonates undergoing surgery for congenital heart disease.Journal of intensive care · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Necrotizing enterocolitis (NEC) is the most common intestinal emergency among premature infants. Risk factors in premature infants include immature intestinal immunity and an intestinal microbiota dominated by hospital-acquired bacteria. Some probiotics have been shown to decrease the incidence of NEC in premature infants. Among term infants, NEC is rare. However, among term infants with cyanotic congenital heart disease (CCHD), the incidence of NEC is similar to that of premature infants but with even greater mortality rates. Mechanisms by which NEC occurs in term infants with CCHD are unknown. Of central interest is the potential role of changes in the intestinal microbiota and whether these can be modified with probiotic bacteria; accordingly, we review the literature, propose hypotheses and present the rationale for future studies involving preliminary probiotic clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.